Literature DB >> 2852234

Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors.

C I Johnston1, F A Mendelsohn, R B Cubela, B Jackson, M Kohzuki, B Fabris.   

Abstract

Two methods of radio-inhibitor binding to tissue membrane homogenates and in vitro autoradiography have been used for ex vivo studies on the inhibition of tissue angiotensin converting enzyme (ACE) following acute and chronic administration of ACE inhibitors. Tissue ACE is differentially inhibited in time and degree in different tissues of the rat. Plasma and kidney ACE are inhibited completely at low doses whereas lung and aorta are only inhibited by 60-70%, even after very high does of ACE inhibitors. In the brain only those structures outside the blood-brain barrier are inhibited at low doses but at high doses perindopril appears able to cross the blood-brain barrier. Similarly, testicular ACE is not inhibited and appears to be protected by a blood-testis barrier. Preliminary results suggest that after chronic administration there is also a variable pattern of induction and inhibition of ACE in different tissues. By relating the degree of tissue inhibition to physiological responses it may be possible to determine the role of local renin-angiotensin systems in regional haemodynamics and in the hypotensive action of ACE inhibitors. Further, the techniques of radioligand inhibitor binding and in vitro autoradiography can be extended to other important cardiovascular enzymes (renin and kallikrein) when suitable high affinity specific inhibitors become available.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2852234

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  12 in total

Review 1.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 3.  Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.

Authors:  J A Balfour; K L Goa
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 4.  Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension. An overview.

Authors:  C M Ferrario
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 5.  Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Authors:  R J Macfadyen; K R Lees; J L Reid
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 6.  Effects of ACE inhibitors on coronary atherosclerosis and restenosis.

Authors:  A D Timmis; B Pitt
Journal:  Br Heart J       Date:  1994-09

Review 7.  Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  P A Todd; A Fitton
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

8.  The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention.

Authors:  M Texter; R S Lees; B Pitt; R E Dinsmore; A C Uprichard
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

9.  Protection of Renal Function with ACE Inhibitors: Experience with Benazepril.

Authors:  J C Aldigier; Y L Meur; P Brunel
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

10.  The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man.

Authors:  J R Wade; P A Meredith; D M Hughes; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.